CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

NACompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

October 22, 2007

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions
Prostate CancerProstatic CancerProstatic NeoplasmsProstate NeoplasmsCancer of the Prostate
Interventions
RADIATION

CyberKnife Stereotactic Radiosurgery - Low Risk

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate

RADIATION

CyberKnife Stereotactic Radiosurgery - Intermediate Risk

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally

Trial Locations (18)

27599

University of North Carolina, Chapel Hill

33449

South Florida Radiation Oncology, Wellington

33461

JFK Comprehensive Cancer Center, Lake Worth

33511

New Millenium CyberKnife, Brandon

36604

Mitchell Cancer Center University of South Alabama, Mobile

37203

Sarah Cannon Research Institute, Nashville

59405

Benefis Health System - Sletten Cancer Institute, Great Falls

60126

Elmhurst Memorial Hospital, Elmhurst

73102

St. Anthony Hospital, Oklahoma City

75701

East Texas Medical Center, Tyler

80026

Colorado Cyberknife, Lafayette

80907

Penrose Cancer Center, Colorado Springs

89128

Comprehensive Cancer Centers of Nevada, Las Vegas

90806

Long Beach Memorial Medical Center, Long Beach

91105

Pasadena Cyberknife Center, Pasadena

92101

CyberKnife Centers of San Diego, San Diego

93721

Community Regional Medical Center, Fresno

08234

AtlantiCare Regional Medical Center, Egg Harbor

All Listed Sponsors
lead

Accuray Incorporated

INDUSTRY

NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry | Biotech Hunter | Biotech Hunter